Medicines for Europe

Last week, we took part in the @REMEDi4ALL #iDR26, focused on accelerating real-world change in medicines repurposing. We brought the perspective of the off-patent sector, especially on unlocking the full potential of value added medicines to improve patient access and outcomes.

What role do we play in building more resilient and secure healthcare systems across Europe? Come and explore at our Annual Conference #MedsforEU26 how our sector represents a strategic partner for health security. ➡️ Register here: shorturl.at/Ndx7q

🗺️ Session 6 of #BIOS26 highlighted how global acceptance and use of biosimilar medicines continue to grow across regions, as regulatory agencies work to further unlock their full potential through a range of initiatives and measures.

🌐 AI is increasingly reshaping how medicines are developed and manufactured, including in the biosimilar space, with the goal of advancing patient care and supporting public health. Spotlight 3 of #BIOS26 explored how the EMA is addressing these changes.

📑 Global regulators are actively embedding the latest scientific advancements into biosimilar regulatory guidance. Session 5 of #BIOS26 explored this latest evolution in biosimilar development.

🧪 How are our healthcare systems keeping pace with the biosimilar opportunity? Session 4 of #BIOS26 focused on rethinking care pathways in the biosimilar era, offering a multi-stakeholder perspective on the importance of bridging policy intention and action.

🎯 How can Europe turn biosimilar foresight into real patient access and system impact? Session 3 of #BIOS26 confirmed that when it comes to biosimilar medicines, preparedness is the missing link between policy ambition and real-world outcomes.

👩🏻‍⚕️ How are biosimilar medicines reshaping retinal care? At #BIOS26, Spotlight session 2 explored the real-world impact of biosimilar medicines, moving beyond theory to what really matters: patients, clinicians, and health systems.

Procurement practices directly influence biosimilar competition and market dynamics across Europe.📦 Session 2 highlighted how better tender design, practical sustainable procurement, and early stakeholder engagement can strengthen competition and deliver better outcomes for all.

🧪 What will it take to secure Europe’s leadership in biosimilar medicines for the next decade? Key health stakeholders and global leaders are gathering today at our Biosimilar Medicines Conference #BIOS26 to shape what comes next. ➡️Read more in our PR: shorturl.at/i3Xcq

#BIOS26 Spotlight 2 focused on unlocking the full patient impact of biosimilar medicines. 👥 The AUGMENT Biosimilars Project (EU4Health) tackles the gap between the proven clinical & economic value of biosimilars and their limited uptake across Europe. Stay tuned for more!

🧪Our Biosimilar Medicines Conference 2026 opened with a high-level panel on keeping Europe competitive while ensuring patient access and sustainable off-patent innovation. Stay tuned for more! #BIOS26

⏰ One week to go! Don’t miss #BIOS26, where leading regulators, industry experts, and European institutions will explore the evolving regulatory landscape and its impact on patient access, competitiveness, and healthcare sustainability. ➡️ shorturl.at/u1b94

🗓️ Our Legal Affairs Conference turns 20! Join us in Athens on 8–9 June 2026 for this milestone edition, bringing together Europe’s top legal experts to discuss the biggest pharmaceutical policy revisions in recent years. ➡️ Register here: shorturl.at/ixhex

Seven Medicines for Europe members are appealing before the European Court of Justice regarding their admissibility on the case concerning the UWWTD to protect patient access to medicines. ➡️ Read the full announcement: shorturl.at/A6NA1

📋 What are the lowest hanging fruits on the way to regulatory convergence to unlock global access to lifesaving biologic medicines?➡️ Discover how regulatory alignment can transform biosimilar access worldwide at #BIOS26: shorturl.at/u1b94

The @EU_Commission claims 66% of wastewater micropollutants come from pharmaceuticals. But a Ramboll review found no studies backing this. Using EMA methodology, the top 4 medicines cited drop from 58% of toxicity to <1%. Stop the clock and assess the impact on patient access.

This week, our honorary former President and Director General joined a healthcare industry roundtable hosted by the European Health Commissioner Olivér Várhelyi. We look forward to working with healthcare partners to help shape a future-proof European health industrial strategy.

💡 What should one expect from the new era in biosimilar regulatory-science? Let’s discuss the latest shift in biosimilar regulatory science and how global agencies are evolving their approach to biosimilar development. ➡️shorturl.at/u1b94

🌍Our Annual Conference #MedsforEU26 will kick off with a high-level panel reflecting on the role of the off-patent medicines industry as a strategic partner for Europe. ➡️ Register here: shorturl.at/Ndx7q